Tumour-Infiltrating Lymphocyte Subsets, PD-L1 Expression, HPV/p16 Status, and Neutrophil-to-Lymphocyte Ratio in Oral Squamous Cell Carcinoma: A Longitudinal Stratified Study of Non-Recurrent and Recurrent Disease
This longitudinal study of 299 Indian oral squamous cell carcinoma patients characterizes the tumor immune microenvironment through TIL subsets, PD-L1, HPV/p16 status, and NLR, revealing that while specific immune markers like FOXP3+ cells correlate with adverse pathology, the immune landscape does not distinguish between recurrent and non-recurrent disease, indicating that immunotherapy eligibility represents a biological dimension distinct from recurrence risk.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is often described as a battle within the body, where the immune system acts as an army of soldiers patrolling the tissues, ready to identify and destroy abnormal cells. In the mouth, a common and aggressive form of cancer called oral squamous cell carcinoma frequently arises, particularly in regions where the use of tobacco and areca nut is widespread. For decades, doctors have relied on looking at the physical appearance of the tumor under a microscope to guess how it might behave, but these visual clues often fail to predict whether the disease will return after surgery. Recently, a new hope has emerged from the field of immunotherapy, a treatment that does not attack the cancer directly but instead removes the brakes the tumor places on the immune system, allowing the body's own defenses to fight back. To know if a patient will respond to this treatment, scientists need to understand the specific environment surrounding the tumor, known as the tumor microenvironment, and determine which immune cells are present and whether the cancer has learned to hide from them.
A team of researchers in India set out to map this complex landscape in nearly three hundred patients with oral cancer. They gathered tissue samples from patients who had undergone surgery at two major cancer centers, carefully separating those whose disease did not return from those whose cancer came back within a year. The scientists examined the tissue for several specific markers: the presence of various types of immune cells, the levels of a protein called PD-L1 that tumors use to disguise themselves, the status of a protein called p16 which can sometimes indicate a viral cause, and a simple blood test ratio that measures systemic inflammation. Their goal was to see if the immune landscape of the tumor could predict which patients would suffer a recurrence and to identify which biological features might make a patient a good candidate for immune-based therapies.
The study revealed a surprising truth about the immune system in these tumors. The researchers found that the immune environment of the cancer looked almost exactly the same whether the patient's disease would eventually return or not. Whether a patient was destined for a cure or a recurrence, their tumors contained similar numbers of immune cells and showed similar levels of the disguise protein. This finding suggests that looking at the immune system in the primary tumor cannot predict who will get sick again; the risk of recurrence is driven by other factors, such as how deeply the cancer invades surrounding tissues or whether it has entered blood vessels. However, this does not mean the immune profile is useless. Instead, the researchers found that the immune landscape is a stable feature that can help doctors decide who should receive immunotherapy, regardless of the risk of the cancer coming back.
One of the most significant discoveries was the role of a specific type of immune cell called a regulatory T cell. These cells act as peacekeepers, normally preventing the immune system from attacking healthy tissue, but in these tumors, they were found in high numbers and were strongly linked to the most dangerous features of the cancer, such as spread to lymph nodes and invasion into blood vessels. The study showed that tumors with high levels of these regulatory cells were also more likely to express the PD-L1 disguise protein. This combination creates a paradoxical state where the tumor is surrounded by a heavy infiltration of immune cells, yet those cells are effectively silenced. It is as if the immune army has arrived at the battlefield but has been ordered to stand down by the enemy, leaving the cancer to grow unchecked. This "inflamed but suppressed" environment is precisely the condition where immunotherapy drugs are designed to work, as they can release the brakes on these silenced cells.
The researchers also investigated the role of a protein called p16, which is often used as a marker for human papillomavirus infection in other types of head and neck cancer. In this group of patients, p16 was found in only a very small number of cases, all of whom had recurrent disease. Interestingly, these rare p16-positive tumors showed a distinct immune profile: they had very low levels of the suppressive regulatory T cells. This suggests that when p16 is present, the tumor environment is less crowded with the cells that usually stop the immune system from working. While the overall number of p16-positive cases was too small to draw broad conclusions about the virus itself, the finding highlights that different biological mechanisms can create different immune landscapes, even within the same type of cancer.
Finally, the team looked at the connection between the tumor's behavior and the body's overall inflammation, measured by a ratio of two types of white blood cells in the blood. They discovered that patients with specific aggressive features in their tumors, such as cancer cells invading blood vessels or spreading in a disorganized pattern, had higher levels of this inflammatory ratio before treatment began. This links the local aggression of the tumor to a systemic signal in the body, suggesting that the tumor sends out chemical distress signals that alter the entire immune system. However, the study did not find a direct link between the specific types of immune cells inside the tumor and this blood ratio, indicating that the two are driven by different mechanisms.
The work of these researchers provides a clearer picture of the biological reality of oral cancer in India. It shows that while the immune system is present in the tumor, it is often held in check by suppressive cells and disguise proteins, a state that offers a clear target for treatment. Crucially, the study demonstrates that the immune profile of a tumor is a reliable guide for selecting patients for immunotherapy, but it is not a crystal ball for predicting recurrence. By understanding that the risk of the disease returning is separate from the tumor's immune characteristics, doctors can better tailor their approach: using immunotherapy to activate the suppressed immune system while relying on traditional surgical and pathological markers to monitor the risk of the cancer coming back. This integrated view helps move beyond guesswork, offering a more precise way to match the right treatment to the right patient.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.